Active Ingredient History
Atomoxetine is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder. The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter. Most common adverse reactions are: nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence, constipation, dry mouth, dizziness, erectile dysfunction, and urinary hesitation. Atomoxetine is a substrate for CYP2D6 and hence concurrent treatment with CYP2D6 inhibitors such as bupropion (Wellbutrin) or fluoxetine (Prozac) is not recommended, as this can lead to significant elevations of plasma atomoxetine levels. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alcohol-Induced Disorders (Phase 1)
Alcoholism (Phase 2)
Alzheimer Disease (Phase 2/Phase 3)
Anxiety Disorders (Phase 4)
Asperger Syndrome (Phase 4)
Atomoxetine Hydrochloride (Phase 2)
Atrophy (Phase 2)
Autistic Disorder (Phase 4)
Autonomic Nervous System Diseases (Phase 3)
Binge-Eating Disorder (Phase 4)
Central Nervous System Stimulants (Phase 2)
Chorea (Phase 2)
Cocaine-Related Disorders (Phase 2)
Cognition (Phase 2)
Cognition Disorders (Phase 3)
Cognitive Dysfunction (Phase 2)
Comorbidity (Phase 4)
Deficiency Diseases (Phase 4)
Depression (Phase 4)
Depressive Disorder (Phase 4)
Diabetes Mellitus, Type 1 (Early Phase 1)
Dopamine beta-Hydroxylase (Phase 3)
Down Syndrome (Phase 2)
Drugs, Investigational (Phase 1)
Dyslexia (Phase 4)
Executive Function (Phase 4)
Fetal Alcohol Spectrum Disorders (Phase 3)
Gait (Phase 3)
Growth and Development (Phase 4)
Healthy Volunteers (Phase 1)
Huntington Disease (Phase 2)
Hypertension (Phase 2)
Hypotension (Phase 4)
Hypotension, Orthostatic (Phase 3)
Marijuana Abuse (Phase 4)
Memory Disorders (Phase 2)
Methamphetamine (Phase 1/Phase 2)
Mood Disorders (Phase 1)
Multiple Sclerosis (Phase 2)
Neoplasms (Phase 3)
Opioid-Related Disorders (Phase 2)
Orthostatic Intolerance (Phase 3)
Parkinson Disease (Phase 4)
Phobia, Social (Phase 2/Phase 3)
Placebos (Phase 2)
Psychological Distress (Phase 1/Phase 2)
Psychotic Disorders (Phase 4)
Pure Autonomic Failure (Phase 1)
Reading (Phase 4)
Schizophrenia (Phase 4)
Sleep Apnea, Obstructive (Phase 2)
Sleep Apnea Syndromes (Phase 2)
Smoking (Phase 2)
Stress Disorders, Post-Traumatic (Phase 4)
Stress, Physiological (Phase 1/Phase 2)
Substance Abuse, Oral (Phase 4)
Substance-Related Disorders (Phase 4)
Syncope, Vasovagal (Phase 4)
Tachycardia (Phase 1/Phase 2)
Tobacco Use Disorder (Phase 1/Phase 2)
Tourette Syndrome (Phase 2)
Whiplash Injuries (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
